Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza.

Bandarage UK, Clark MP, Perola E, Gao H, Jacobs MD, Tsai A, Gillespie J, Kennedy JM, Maltais F, Ledeboer MW, Davies I, Gu W, Byrn RA, Nti Addae K, Bennett H, Leeman JR, Jones SM, O'Brien C, Memmott C, Bennani Y, Charifson PS.

ACS Med Chem Lett. 2017 Jan 18;8(2):261-265. doi: 10.1021/acsmedchemlett.6b00487. eCollection 2017 Feb 9.

2.

Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2.

Farmer LJ, Clark MP, Boyd MJ, Perola E, Jones SM, Tsai A, Jacobs MD, Bandarage UK, Ledeboer MW, Wang T, Deng H, Ledford B, Gu W, Duffy JP, Bethiel RS, Shannon D, Byrn RA, Leeman JR, Rijnbrand R, Bennett HB, O'Brien C, Memmott C, Nti-Addae K, Bennani YL, Charifson PS.

ACS Med Chem Lett. 2017 Jan 20;8(2):256-260. doi: 10.1021/acsmedchemlett.6b00486. eCollection 2017 Feb 9.

3.

Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.

Tsai AW, McNeil CF, Leeman JR, Bennett HB, Nti-Addae K, Huang C, Germann UA, Byrn RA, Berlioz-Seux F, Rijnbrand R, Clark MP, Charifson PS, Jones SM.

Antimicrob Agents Chemother. 2015 Oct;59(10):6007-16. doi: 10.1128/AAC.00781-15. Epub 2015 Jul 13.

4.

Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.

Byrn RA, Jones SM, Bennett HB, Bral C, Clark MP, Jacobs MD, Kwong AD, Ledeboer MW, Leeman JR, McNeil CF, Murcko MA, Nezami A, Perola E, Rijnbrand R, Saxena K, Tsai AW, Zhou Y, Charifson PS.

Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82. doi: 10.1128/AAC.04623-14. Epub 2014 Dec 29.

5.

Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.

Clark MP, Ledeboer MW, Davies I, Byrn RA, Jones SM, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage UK, Boyd MJ, Bethiel RS, Court JJ, Deng H, Duffy JP, Dorsch WA, Farmer LJ, Gao H, Gu W, Jackson K, Jacobs DH, Kennedy JM, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker MW, Bennett HB, Leeman JR, McNeil C, Taylor WP, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson PS.

J Med Chem. 2014 Aug 14;57(15):6668-78. doi: 10.1021/jm5007275. Epub 2014 Jul 24.

PMID:
25019388
6.

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL.

J Infect Dis. 2008 Sep 15;198(6):800-7. doi: 10.1086/591141.

PMID:
18637752
7.

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.

Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C.

Antimicrob Agents Chemother. 2006 Mar;50(3):899-909.

8.
9.
10.
11.

Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir.

Kiessling AA, Fitzgerald LM, Zhang D, Chhay H, Brettler D, Eyre RC, Steinberg J, McGowan K, Byrn RA.

AIDS Res Hum Retroviruses. 1998 Apr;14 Suppl 1:S33-41.

PMID:
9581882
12.

HIV-1 in semen: an isolated virus reservoir.

Byrn RA, Zhang D, Eyre R, McGowan K, Kiessling AA.

Lancet. 1997 Oct 18;350(9085):1141. No abstract available.

PMID:
9343504
13.

The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1.

Yamaguchi K, Papp B, Zhang D, Ali AN, Agrawal S, Byrn RA.

AIDS Res Hum Retroviruses. 1997 May 1;13(7):545-54.

PMID:
9135872
14.

Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments.

Kandimalla ER, Manning A, Zhao Q, Shaw DR, Byrn RA, Sasisekharan V, Agrawal S.

Nucleic Acids Res. 1997 Jan 15;25(2):370-8.

15.

Clinical isolates of HIV-1 contain few pre-existing proteinase inhibitor resistance-conferring mutations.

Yamaguchi K, Byrn RA.

Biochim Biophys Acta. 1995 Dec 6;1253(2):136-40.

PMID:
8519793
16.

A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.

Chamow SM, Zhang D, Tan XY, Mhatre SM, Marsters SA, Peers DH, Byrn RA, Ashkenazi A, Junghans RP.

J Hematother. 1995 Oct;4(5):439-46.

PMID:
8581382
17.

Design, biochemical, biophysical and biological properties of cooperative antisense oligonucleotides.

Kandimalla ER, Manning A, Lathan C, Byrn RA, Agrawal S.

Nucleic Acids Res. 1995 Sep 11;23(17):3578-84.

18.

Stimulation of HIV expression by intracellular calcium pump inhibition.

Papp B, Byrn RA.

J Biol Chem. 1995 Apr 28;270(17):10278-83.

19.

HIV type 1 protease activation of NF-kappa B within T lymphoid cells.

Zhang D, Zhang N, Wick MM, Byrn RA.

AIDS Res Hum Retroviruses. 1995 Feb;11(2):223-30.

PMID:
7742037
20.
21.

Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors.

Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ, Groopman JE, Capon DJ, Byrn RA, Finer MH.

Blood. 1994 Nov 1;84(9):2878-89.

PMID:
7949163
22.

A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.

Chamow SM, Zhang DZ, Tan XY, Mhatre SM, Marsters SA, Peers DH, Byrn RA, Ashkenazi A, Junghans RP.

J Immunol. 1994 Nov 1;153(9):4268-80.

PMID:
7930627
23.

Fluorescent primers allow direct confirmation of restriction enzyme cleavage of PCR products.

Yamaguchi K, Zhang D, Byrn RA.

Biotechniques. 1994 Oct;17(4):649-50, 652. No abstract available.

PMID:
7833017
24.

Stimulation of human immunodeficiency virus type 1 expression by ceramide.

Papp B, Zhang D, Groopman JE, Byrn RA.

AIDS Res Hum Retroviruses. 1994 Jul;10(7):775-80.

PMID:
7986582
25.

A modified nonradioactive method for northern blot analysis.

Yamaguchi K, Zhang D, Byrn RA.

Anal Biochem. 1994 May 1;218(2):343-6.

PMID:
7521144
26.

Comparison of the immune response to recombinant gp120 in humans and chimpanzees.

Berman PW, Eastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, Schwartz D, Gorse G, Belshe R, Clements ML, Byrn RA.

AIDS. 1994 May;8(5):591-601.

PMID:
7520248
27.

Conjugation of soluble CD4 without loss of biological activity via a novel carbohydrate-directed cross-linking reagent.

Chamow SM, Kogan TP, Peers DH, Hastings RC, Byrn RA, Ashkenazi A.

J Biol Chem. 1992 Aug 5;267(22):15916-22.

28.

CD4 immunoadhesins in anti-HIV therapy: new developments.

Chamow SM, Duliege AM, Ammann A, Kahn JO, Allen JD, Eichberg JW, Byrn RA, Capon DJ, Ward RH, Ashkenazi A.

Int J Cancer Suppl. 1992;7:69-72. Review.

PMID:
1428410
29.

An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.

Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA.

J Immunol. 1991 Jun 15;146(12):4325-32.

PMID:
1710248
30.

Characterization of autoantibodies to the CD4 molecule in human immunodeficiency virus infection.

Sekigawa I, Groopmen JE, Allan JD, Ikeuchi K, Biberfield G, Takatsuki K, Byrn RA.

Clin Immunol Immunopathol. 1991 Jan;58(1):145-53.

PMID:
1983967
31.

Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments.

Chamow SM, Peers DH, Byrn RA, Mulkerrin MG, Harris RJ, Wang WC, Bjorkman PJ, Capon DJ, Ashkenazi A.

Biochemistry. 1990 Oct 23;29(42):9885-91.

PMID:
2125484
33.

Infection of nonlymphoid cells by human immunodeficiency virus type 1 or type 2.

Ikeuchi K, Kim S, Byrn RA, Goldring SR, Groopman JE.

J Virol. 1990 Sep;64(9):4226-31.

34.
35.

Biological properties of a CD4 immunoadhesin.

Byrn RA, Mordenti J, Lucas C, Smith D, Marsters SA, Johnson JS, Cossum P, Chamow SM, Wurm FM, Gregory T, Groopman JE, Capon DJ.

Nature. 1990 Apr 12;344(6267):667-70.

PMID:
1970124
36.

Effects of recombinant soluble CD4 (rCD4) on HIV-1 infection of monocyte/macrophages.

Harbison MA, Gillis JM, Pinkston P, Byrn RA, Rose RM, Hammer SM.

J Infect Dis. 1990 Jan;161(1):1-6.

PMID:
2295841
37.

Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.

Byrn RA, Sekigawa I, Chamow SM, Johnson JS, Gregory TJ, Capon DJ, Groopman JE.

J Virol. 1989 Oct;63(10):4370-5.

38.
39.

CD4+ lymphocyte function with early human immunodeficiency virus infection.

Gurley RJ, Ikeuchi K, Byrn RA, Anderson K, Groopman JE.

Proc Natl Acad Sci U S A. 1989 Mar;86(6):1993-7.

40.

Designing CD4 immunoadhesins for AIDS therapy.

Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, et al.

Nature. 1989 Feb 9;337(6207):525-31.

PMID:
2536900
41.

A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus.

Ezekowitz RA, Kuhlman M, Groopman JE, Byrn RA.

J Exp Med. 1989 Jan 1;169(1):185-96.

42.

Antigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutants.

Muggeridge MI, Isola VJ, Byrn RA, Tucker TJ, Minson AC, Glorioso JC, Cohen GH, Eisenberg RJ.

J Virol. 1988 Sep;62(9):3274-80.

43.

Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.

Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ.

Science. 1987 Dec 18;238(4834):1704-7.

PMID:
3500514
44.

Supplemental Content

Support Center